Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx, page-14

Tony Keating, CEO and Managing Director said: “We are delighted to have secured FDA clearance for SleepCheckRx. With more than 20 million American adults suffering from sleep apnoea and the majority of those not knowing that they have the condition, this clearance unlocks a significant market opportunity for ResApp. By using SleepCheckRx, physicians will have the opportunity to screen their patients conveniently and quickly for sleep apnoea, helping their patients take the first step to getting treatment.” #